A Study to Evaluate the Correlation Between Frailty, Adverse Outcome and Clonal Hematopoiesis


About this study

The purpose of this study is to assess the frailty and clonal hematopoiesis (CH) in hematology malignancy patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • All patients ≥ 18 years old.
  • With a diagnosis of hematology malignancy.
  • Willing and able to provide written informed consent.

Exclusion Criteria:

  • < 18 years old.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mrinal Patnaik, M.B.B.S.

Open for enrollment

Contact information:

Mrinal Patnaik M.B.B.S.

(507) 284-5096


More information


Publications are currently not available

Mayo Clinic Footer